Every trade that managers of Foxo Technologies Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Health Care sector. Foxo Technologies Inc. has had no insider filing for more than a year; the last one goes back to 24 July 2024.
Looking back to 2022, when coverage begins, insiders filed no purchases and 3 sales. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists revenue at 16.4 m USD and net income at -12.4 m USD.
Elsewhere in the same sector, our signals recently picked up insider purchases at Dynavox Group AB and EssilorLuxottica. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
FY ended December 2025 · cache
25 of 30 declarations
Foxo Technologies Inc. is a NASDAQ-listed company focused on developing technological solutions in the biotechnology sector. It aims to transform health and wellness through data science-based innovations.
Purchases our model currently ranks for the recommendations list.
All recommendations| Fiscal year end | Revenue | Net income | Diluted EPS | Filing |
|---|---|---|---|---|
| Dec 2025 | 16.4 m USD | -12.4 m USD | n.d. | 10-K |
| Dec 2024 | 4.1 m USD | -12.4 m USD | n.d. | 10-K |
| Dec 2023 | 145,291 USD | -26.5 m USD | n.d. | 10-K |
| Dec 2022 | 511,000 USD | -95.3 m USD | n.d. | 10-K |
| Dec 2021 | 120,000 USD | -38.5 m USD | n.d. | 10-K |
Amounts in USD, as filed (forms 10-K, 20-F or 40-F). Source: SEC EDGAR.